{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"1","value":"11"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"}],"units":"Participants"}],"description":"Neutrophil engraftment was defined as the first day of 3 consecutive days where ANC (absolute neutrophil count) was higher than 500/ul. The two drug treatments in this cross-over design were administered on 2 subsequent days (Day -3 and Day -2). No per arm analysis was performed.\n\nSince the two treatments were administered consecutively with 1 day rest, the time to engraftment and engraftment rate was measured after both treatments were administered.","dispersionType":"Standard Deviation","groups":[{"description":"Open-label, randomized, cross-over design study where Propylene Glycol Free Melphalan and Alkeran were assessed in the same multiple myeloma patients undergoing transplantation.","id":"OG000","title":"Open-label, Randomized, Crossover Study"}],"paramType":"MEAN","populationDescription":"The intent-to-treat (ITT) population was defined as all patients who received at least one dose of Melphalan HCl for Injection (Propylene Glycol-Free) or Alkeran for Injection. All efficacy analyses were to be performed on the ITT population.","reportingStatus":"POSTED","timeFrame":"30 days","title":"Determination of Engraftment Following Melphalan-alkeran Sequence and Alkeran-melphalan Sequence Followed by ASCT","type":"SECONDARY","unitOfMeasure":"days"}